Clinical Trial Update: Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel [Phase 2]

View source ↗

Summary

A Phase 2 trial of cabazitaxel plus buparlisib for metastatic castration-resistant prostate cancer previously treated with docetaxel has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Buparlisib (buparlisib)
• Jevtana (cabazitaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Advanced Prostate Cancer | Phase 2 | Status: WITHDRAWN